Truist Securities Initiates Coverage On RayzeBio with Buy Rating, Announces Price Target of $29
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has initiated coverage on RayzeBio (NASDAQ:RYZB) with a Buy rating and a price target of $29.
October 10, 2023 | 12:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RayzeBio has received a Buy rating from Truist Securities with a price target of $29.
The Buy rating and price target set by Truist Securities indicates a positive outlook for RayzeBio. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100